Oncology & Cancer

Drug targeting BRAF mutation slows thyroid cancer, too

In the era of precision medicine, targeting the mutations driving cancer growth, rather than the tumor site itself, continues to be a successful approach for some patients. In the latest example, researchers from Penn Medicine ...

Oncology & Cancer

Thyroid cancer surges—is TMI responsible?

In most cases, the cause of thyroid cancer is unknown, according to Dr. David Goldenberg, chief of otolaryngology-head and neck surgery at Penn State Health. But for years, the vast majority of his thyroid cancer patients ...

Oncology & Cancer

Antineoplastic agents associated with thyroid dysfunction

Antineoplastic agents such as immunotherapies and targeted therapies that specifically target signaling pathways in cancer cells are associated with thyroid dysfunction in 20%-50% of cancer patients taking them, which can ...

page 8 from 24